Smoking-induced ventral striatum dopamine release

American Journal of Psychiatry

Volumn 161, Issue 7, 2004, Pages 1211-1218

  Brody, Arthur L ^a   Olmstead, Richard E ^b   London, Edythe D ^b   Farahi, Judah ^b   Meyer, Jeffrey H ^b   Grossman, Paul ^b   Lee, Grace S ^b   Huang, Joe ^b   Hahn, Emily L ^b   Mandelkern, Mark A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; DOPAMINE; NICOTINE; RACLOPRIDE;

ADULT; AGED; ARTICLE; BINDING AFFINITY; BOLUS INJECTION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; FEMALE; HUMAN; MALE; NUCLEUS ACCUMBENS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; REINFORCEMENT; SMOKING; WITHDRAWAL SYNDROME;

ADULT; BASAL GANGLIA; DOPAMINE; FEMALE; HUMANS; MALE; NICOTINE; NICOTINIC AGONISTS; RACLOPRIDE; RECEPTORS, DOPAMINE D2; REINFORCEMENT (PSYCHOLOGY); SMOKING; TOBACCO USE DISORDER; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 3042785720     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.161.7.1211     Document Type: Article

References (68)

1. Leshner AI, Koob GF: Drugs of abuse and the brain. Proc Assoc Am Physicians 1999; 111:99-108
2. Koob GF: Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992; 13:177-184
3. Di Chiara G, Imperato A: Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988; 85:5274-5278
4. Pontieri FE, Tanda G, Orzi F, Di Chiara G: Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996; 382:255-257
5. Sziraki I, Lipovac MN, Hashim A, Sershen H, Allen D, Cooper T, Czobor P, Lajtha A: Differences in nicotine-induced dopamine release and nicotine pharmacokinetics between Lewis and Fischer 344 rats. Neurochem Res 2001; 26:609-617
6. Damsma G, Day J, Fibiger HC: Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. Eur J Pharmacol 1989; 168:363-368
7. Corrigall WA, Franklin KB, Coen KM, Clarke PB: The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) 1992; 107:285-289
8. 3H]dopamine release by nicotine in rat nucleus accumbens. J Neurochem 1987; 49:1449-1454
9. Dewey SL, Brodie JD, Gerasimov M, Horan B, Gardner EL, Ashby CRJ: A pharmacologic strategy for the treatment of nicotine addiction. Synapse 1999; 31:76-86
10. Salokangas RKR, Vilkman H, Ilonen T, Taiminen T, Bergman J, Haaparanta M, Solin O, Alanen A, Syvälahti E, Hietala J: High levels of dopamine activity in the basal ganglia of cigarette smokers. Am J Psychiatry 2000; 157:632-634
11. Laruelle M: Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000; 20:423-451
12. Vallone D, Picetti R, Borrelli E: Structure and function of dopamine receptors. Neurosci Biobehav Rev 2000; 24:125-132
13. 11C]raclopride: combined PET-microdialysis studies. J Cereb Blood Flow Metab 1997; 17:932-942
14. 11C]raclopride at dopamine receptors in human subjects. Am J Psychiatry 1997; 154:1209-1213
15. Drevets WC, Price JC, Kupfer DJ, Kinahan PE, Lopresti B, Holt D, Mathis C: PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum. Neuropsychopharmacology 1999; 21:694-709
16. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M: Imaging human mesolimbic dopamine transmission with positron emission tomography, part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003; 23:285-300
17. Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, Price JL, Mathis CA: Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001; 49:81-96
18. 11C]raclopride in the human brain. Synapse 1994; 16:255-262
19. Cumming P, Rosa-Neto P, Watanabe H, Smith D, Bender D, Clarke PBS, Gjedde A: Effects of acute nicotine on hemodynamics and binding of [11-C]raclopride to dopamine D2,3 receptors in pig brain. Neuroimage 2003; 19:1127-1136
20. Volkow ND, Fowler JS, Gatley SJ, Dewey SL, Wang GJ, Logan J, Ding YS, Franceschi D, Gifford A, Morgan A: Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. Synapse 1999; 31:59-66
21. 3H]raclopride binding to the dopamine D2 receptor. Arch Pharm Res 2000; 23:360-366
22. Hartvig P, Torstenson R, Tedroff J, Watanabe Y, Fasth KJ, Bjurling P, Langstrom B: Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography. J Neural Transm 1997; 104: 329-339
23. 11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab 1997; 17: 437-447
24. de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ: Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001; 293: 1164-1166
25. Kjaer TW, Bertelsen C, Piccini P, Brooks D, Alving J, Lou HC: Increased dopamine tone during meditation-induced change of consciousness. Brain Res Cogn Brain Res 2002; 13:255-259
26. Koepp MJ, Gunn RN, Lawrence AD, Cunningham VJ, Dagher A, Jones T, Brooks DJ, Bench CJ, Grasby PM: Evidence for striatal dopamine release during a video game. Nature 1998; 393: 266-268
27. 11C]raclopride in the human brain in response to methylphenidate. J Nucl Med 1999; 40:1285-1291
28. 11C]-raclopride in vivo: a test-retest analysis. J Cereb Blood Flow Metab 1999; 19:210-217
29. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), version 2. New York, New York State Psychiatric Institute, Biometrics Research, 1995
30. Jarvik ME, Madsen DC, Olmstead RE, Iwamoto-Schaap PN, Elins JL, Benowitz NL: Nicotine blood levels and subjective craving for cigarettes. Pharmacol Biochem Behav 2000; 66:553-558
31. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA: Manual for the State-Trait Anxiety Inventory. Palo Alto, Calif, Consulting Psychologists Press, 1983
32. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296
33. 11C]raclopride binding. J Cereb Blood Flow Metab 1998; 18:941-950
34. Schuh KJ, Stitzer ML: Desire to smoke during spaced smoking intervals. Psychopharmacology (Berl) 1995; 120:289-295
35. Farde L, Hall H, Ehrin E, Sedvall G: Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986; 231:258-261
36. Ehrin E, Gawell L, Hogberg T, Depaulis T, Strom P: Synthesis of [methoxy-H-3]- and [methoxy-C-11]-labeled raclopride-specific dopamine-D2 receptor ligands. J Labelled Comp Radiopharm 1987; 24:931-940
37. Woods RP, Mazziotta JC, Cherry SR: MRI-PET registration with automated algorithm. J Comp Assist Tomogr 1993; 17:536-546
38. Wang GJ, Volkow ND, Levy AV, Fowler JS, Logan J, Alexoff D, Hitzemann RJ, Schyler DJ: MR-PET image coregistration for quantitation of striatal dopamine D2 receptors. J Comp Assist Tomogr 1996; 20:423-428
39. Lammertsma AA, Hume SP: Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4:153-158
40. 11C]raclopride: optimization and signal-to-noise considerations. J Nucl Med 2000; 41:522-530
41. Pohjalainen T, Rinne JO, Någren K, Syvälahti E, Hietala J: Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. Am J Psychiatry 1998; 155:768-773
42. Kaasinen V, Vilkman H, Hietala J, Nagren K, Helenius H, Olsson H, Farde L, Rinne J: Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. Neurobiol Aging 2000; 21:683-688
43. Le Foll B, Schwartz JC, Sokoloff P: Disruption of nicotine conditioning by dopamine D-3 receptor ligands. Mol Psychiatry 2003; 8:225-230
44. Weiss F, Martin-Fardon R, Ciccocioppo R, Kerr TM, Smith DL, Ben Shahar O: Enduring resistance to extinction of cocaine-seeking behavior induced by drug-related cues. Neuropsychopharmacology 2001; 25:361-372
45. Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P: Selective inhibition of cocaine-seeking behaviour by a partial dopamine D-3 receptor agonist. Nature 1999; 400:371-375
46. Duong A, Weingarten HP: Dopamine antagonists act on central, but not peripheral, receptors to inhibit sham and real feeding. Physiol Behav 1993; 54:449-454
47. Chance WT, Foley-Nelson T, Nelson JL, Fischer JE: Neurotransmitter alterations associated with feeding and satiety. Brain Res 1987; 416:228-234
48. Rodriguez-Manzo G: Yohimbine interacts with the dopaminergic system to reverse sexual satiation: further evidence for a role of sexual motivation in sexual exhaustion. Eur J Pharmacol 1999; 372:1-8
49. Fiorino DF, Coury A, Phillips AG: Dynamic changes in nucleus accumbens dopamine efflux during the Coolidge effect in male rats. J Neurosci 1997; 17:4849-4855
50. Holm KJ, Spencer CM: Bupropion: a review of its use in the management of smoking cessation. Drugs 2000; 59:1007-1024
51. Horst WD, Preskorn SH: Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 1998; 51:237-254
52. Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S: Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl) 2002; 163:102-105
53. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC: Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology 1989; 2:273-279
54. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, et al: Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56:395-401
55. Dong J, Blier P: Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl) 2001; 155:52-57
56. Jarvik ME, Caskey NH, Wirshing WC, Madsen DC, Iwamoto-Schaap PN, Elins JL, Eisenberger NI, Olmstead RE: Bromocriptine reduces cigarette smoking. Addiction 2000; 95:1173-1183
57. Houtsmuller EJ, Thornton JA, Stitzer ML: Effects of selegiline (I-deprenyl) during smoking and short-term abstinence. Psychopharmacology (Berl) 2002; 163:213-220
58. Brauer LH, Cramblett MJ, Paxton DA, Rose JE: Haloperidol reduces smoking of both nicotine-containing and denicotinized cigarettes. Psychopharmacology (Berl) 2001; 159:31-37
59. Caskey NH, Jarvik ME, Wirshing WC: The effects of dopaminergic D2 stimulation and blockade on smoking behavior. Exp Clin Psychopharmacol 1999; 7:72-78
60. Mathew RJ, Wilson WH: Substance abuse and cerebral blood flow. Am J Psychiatry 1991; 148:292-305
61. Boyajian RA, Otis SM: Acute effects of smoking on human cerebral blood flow: a transcranial Doppler ultrasonography study. J Neuroimaging 2000; 10:204-208
62. Rose JE, Behm FM, Westman EC, Mathew RJ, London ED, Hawk TC, Turkington TG, Coleman RE: PET studies of the influences of nicotine on neural systems in cigarette smokers. Am J Psychiatry 2003; 160:323-333; correction, 160:810
63. Zubieta J, Lombardi U, Minoshima S, Guthrie S, Ni L, Ohl LE, Koeppe RA, Domino EF: Regional cerebral blood flow effects of nicotine in overnight abstinent smokers. Biol Psychiatry 2001; 49:906-913
64. Domino EF, Minoshima S, Guthrie S, Ohl L, Ni L, Koeppe RA, Zubietal K: Nicotine effects on regional cerebral blood flow in awake, resting tobacco smokers. Synapse 2000; 38:313-321
65. Ghatan PH, Ingvar M, Eriksson L, Stone-Elander S, Serrander M, Ekberg K, Wahren J: Cerebral effects of nicotine during cognition in smokers and non-smokers. Psychopharmacology (Berl) 1998; 136:179-189
66. Goerendt IK, Messa C, Lawrence AD, Grasby PM, Piccini P, Brooks DJ: Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. Brain 2003; 126:312-325
67. Ouchi Y, Yoshikawa E, Futatsubashi M, Okada H, Torizuka T, Sakamoto M: Effect of simple motor performance on regional dopamine release in the striatum in Parkinson disease patients and healthy subjects: a positron emission tomography study. J Cereb Blood Flow Metab 2002; 22:746-752
68. Wang GJ, Volkow ND, Fowler JS, Franceschi D, Logan J, Pappas NR, Wong CT, Netusil N: PET studies of the effects of aerobic exercise on human striatal dopamine release. J Nucl Med 2000; 41:1352-1356